The Advanced Lung Cancer Inflammation Index as a Prognostic Indicator in Patients With Unresectable Hepatocellular Carcinoma Receiving Atezolizumab and Bevacizumab Therapy

Key Points

• To evaluate the Advanced Lung Cancer Inflammation Index (ALI) as a prognostic tool in patients with unresectable hepatocellular carcinoma (u-HCC).
• Retrospective analysis of u-HCC patients receiving Atezolizumab and Bevacizumab therapy
• Assessment of pretreatment ALI values and their association with survival and disease control
• High pretreatment ALI values associated with improved survival rates
• Increased disease control observed in patients with high ALI
• Potential utility of ALI as a prognostic marker in clinical management